Apyx Medical Inc (APYX)vsAstraZeneca PLC (AZN)
APYX
Apyx Medical Inc
$3.06
-8.11%
HEALTHCARE · Cap: $144.73M
AZN
AstraZeneca PLC
$184.74
-1.40%
HEALTHCARE · Cap: $287.11B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 111055% more annual revenue ($58.74B vs $52.84M). AZN leads profitability with a 17.4% profit margin vs -21.2%. APYX appears more attractively valued with a PEG of 0.59. AZN earns a higher WallStSmart Score of 64/100 (C+).
APYX
Hold40
out of 100
Grade: F
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+44.5%
Fair Value
$7.06
Current Price
$3.06
$4.00 discount
Margin of Safety
+4.0%
Fair Value
$214.34
Current Price
$184.74
$29.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 34.7% year-over-year
Growing faster than its price suggests
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.8B in free cash flow
Areas to Watch
Trading at 8.7x book value
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 0.1%
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : APYX
The strongest argument for APYX centers on Revenue Growth, PEG Ratio. Revenue growth of 34.7% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bear Case : APYX
The primary concerns for APYX are Price/Book, EPS Growth, Market Cap.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Key Dynamics to Monitor
APYX profiles as a hypergrowth stock while AZN is a value play — different risk/reward profiles.
APYX carries more volatility with a beta of 1.54 — expect wider price swings.
APYX is growing revenue faster at 34.7% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 40/100), backed by strong 17.4% margins. APYX offers better value entry with a 44.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Apyx Medical Inc
HEALTHCARE · MEDICAL DEVICES · USA
Apyx Medical Corporation, an energy technology company, develops, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. The company is headquartered in Clearwater, Florida.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?